Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-756: Pembrolizumab vs placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy in high-risk early-stage ER+/HER2– breast cancer
2017-004869-27Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoint: Pathological Complete Response Rate (ypT0/Tis ypN0). Started Jun 2018; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-004869-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004869-27.